卡格列净或沙库巴曲缬沙坦钠片联合阿托伐他汀在急性心肌梗死介入治疗后的应用效果观察  

Observation on the application effect of Canagliflozin or Sacubitril valsartan sodium tablets combined with Atorvastatin after acute myocardial infarction intervention

作　　者：朱颖颖 顾钰[1] ZHU Yingying;GU Yu(Department of Infection Control,Rugao People's Hospital,Nantong,Jiangsu 226500,China)

机构地区：[1]如皋市人民医院感控科,江苏南通226500

出　　处：《医药前沿》2025年第12期13-15,19,共4页Journal of Frontiers of Medicine

基　　金：2023年如皋市指导性科技攻关计划项目[SRGS(23)008]。

摘　　要：目的观察钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂卡格列净或沙库巴曲缬沙坦钠片联合阿托伐他汀在急性心肌梗死介入治疗后的应用效果。方法回顾性分析2022年7月—2023年6月如皋市人民医院收治的150例急性心肌梗死患者的临床资料。根据治疗方法不同分为对照组、观察A组、观察B组各50例。对照组采用常规治疗方法(调脂、降压、抗感染)并服用氯吡格雷和阿司匹林,观察A组在对照组治疗基础上采用沙库巴曲缬沙坦钠片联合阿托伐他汀治疗,观察B组在对照组治疗基础上采用卡格列净联合阿托伐他汀治疗,三组患者均持续治疗4周。比较三组治疗前后心肌酶谱变化,心功能指标恢复情况,疗效及不良反应发生率。结果治疗后,三组肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白Ⅰ(cTnⅠ)、肌酸激酶(CK)、左心室收缩末期容积(LVESV)、左心室舒张末期容积(LVEDV)水平均下降,观察B组各指标水平低于对照组和观察A组(P<0.05);三组左心室射血分数(LVEF)升高,观察B组LVEF水平高于对照组和观察A组(P<0.05);观察B组治疗总有效率高于对照组和观察A组,且观察A组高于对照组(P<0.05)。三组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论急性心肌梗死介入治疗后,卡格列净联合阿托伐他汀治疗方法在改善患者心功能、促进心肌修复及降低心肌酶谱水平方面优于沙库巴曲缬沙坦钠片联合阿托伐他汀的治疗方法,2种联合治疗方法安全性均较高。Objective To observe the application effect of sodium-glucose co-transporter 2(SGLT-2)inhibitor Canagliflozin or Sacubitril valsartan sodium tablets combined with Atorvastatin after acute myocardial infarction intervention.Methods A retrospective analysis was conducted on the clinical data of 150 patients with acute myocardial infarction admitted to Rugao People's Hospital from July 2022 to June 2023.According to different treatment methods,the patients were divided into a control group,observation group A,and observation group B,with 50 cases in each group.The control group received conventional treatment(lipid regulation,blood pressure control,anti-infection)combined with Clopidogrel and Aspirin,the observation group A received Sacubitril valsartan sodium tablets combined with Atorvastatin on the basis of the control group's treatment,the observation group B received Canagliflozin combined with Atorvastatin on the basis of the control group's treatment,all three groups were treated for 4 weeks.The changes in myocardial enzyme profiles,cardiac function indicators,treatment efficacy,and the incidence of adverse reactions were compared before and after treatment.Results After treatment,the levels of creatine kinase-myocardial band(CK-MB),cardiac troponin I(cTnI),creatine kinase(CK),left ventricular end-systolic volume(LVESV),left ventricular end-diastolic volume(LVEDV)decreased in all three groups,and the levels of each index in the observation group B were lower than those in the control group and the observation group A(P<0.05);the left ventricular ejection fraction(LVEF)levels increased in all three groups,and the LVEF levels in the observation group B were lower than those in the control group and the observation group A(P<0.05);the total effective rate of treatment in observation group B was higher than that in the control group and the observation group A,and the observation group A was significantly higher than the control group(P<0.05).There was no statistically significant difference in the total incidenc

关 键 词：急性心肌梗死 钠-葡萄糖协同转运蛋白2 沙库巴曲缬沙坦钠片 阿托伐他汀 心功能 心肌酶谱 

分 类 号：R541[医药卫生—心血管疾病]